MTSR Metsera Therapeutics: Long-Term Debt to Capital Coefficient

Symbol and logo of brand Metsera Therapeutics (MTSR)

Metsera Inc (MTSR) is a startup with unstable cash flows due to active expenditures on clinical trials for obesity treatments. The scaling potential here is immense: once the formula is registered, low production costs coupled with high demand will ensure colossal margins. The company is fighting for niche leadership through patent wars and formula efficiency. The share price visualized below stands at 0.00.

MTSR - Metsera, Inc. Long-Term Debt to Equity over the range 02/01/2025 - 11/29/2025

Comprehensive metric breakdowns and analytics for Metsera Inc (MTSR)

- price and consensus price forecast:
Quote Chart Metsera, Inc.|MTSR - Analyst Consensus Forecast
- market capitalization data:
Market Value Metsera Inc|MTSR - Enterprise Value
- book capitalization data:
Book Value per Share Metsera|MTSR - Company Book Value|Market Value to Book Value metsera.com|MTSR - Aggregate Company Assets
- debt and liquidity data:
Total Debt to Equity Ratio Metsera Inc|MTSR - Long-Term Debt to Capital|Short-Term Debt to Capital metsera.com|MTSR - Company Total Debt|Debt to Net Assets Ratio Metsera Inc
Initial company analysis:Metsera, Inc.
Core merchandise of Metsera Inc

This indicator determines the share of long-term credit obligations within the equity structure, allowing for an assessment of financial leverage and balance sheet stability. The trend of the long-term debt-to-equity ratio reflects Metsera Inc (MTSR) dependence on borrowed funds to finance costly clinical trials in the hyper-competitive anti-obesity drug segment, where development speed critically impacts capitalization.

Competing companies

Long-Term Liabilities to Equity Ascendis Pharma AS|Madrigal Pharma (MDGL) - Long-Term Debt to Capital|Long-Term Debt to Capital Coefficient Corcept Therapeutics Corp (CORT)|Long-Term Debt to Capital RYTM (Rhythm Pharmaceuticals)|akerotx.com - Long-Term Debt to Capital|Long-Term Debt to Equity MoonLake (MLTX)|CRNX: Long-Term Debt to Capital Coefficient|NAMS (NewAmsterdam Pharma N.V.) - Long-Term Debt to Equity|Soleno Therapeutics Corp (SLNO) - Long-Term Debt to Equity Ratio|FOLD (Amicus Therapeutics) - Long-Term Debt to Capital|Long-Term Debt to Capital 89bio.com (ETNB)|Agios Pharmaceuticals, Inc. (AGIO) - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient GPCR (Structure Therapeutics Inc)|MiMedx Group - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Rezolute Bio RZLT|LXRX (Lexicon Pharmaceuticals) - Long-Term Debt to Capital|mbxbio.com (MBX) - Long-Term Liabilities to Capital|ALT - Long-Term Debt to Equity Ratio|Aardvark Therapeutics Inc. (AARD) - Long-Term Loans to Capital Ratio|SGMT (Sagimet) - Long-Term Debt to Capital|Long-Term Debt to Capital BioAge Labs, Inc|Long-Term Debt to Capital Biomea Fusion, Inc. (BMEA)|Long-Term Debt to Equity QNCX (quincetx.com)|GUTS: Long-Term Debt to Equity|vTv Therapeutics, Inc. - Long-Term Liabilities to Capital|ATPC - Long-Term Debt to Equity|PLUR - Long-Term Debt to Equity|synlogictx.com - Long-Term Debt to Capital|LPCN (lipocine.com) - Ratio of Long-Term Indebtedness to Capital|MTNB: Long-Term Debt to Equity|Ratio of Long-Term Indebtedness to Capital SPRB|Long-Term Debt to Equity GLTO (Galecto Corp)|Long-Term Debt to Equity Ratio CTCX (Carmell Therapeutics)|Lumos Pharma, Inc. - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio organovo.com ONVO|RDUS (Radius Recycling) - Long-Term Debt to Capital